Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-phase Clinical Trials

Overview

Journal Proc Am Thorac Soc

Specialty Pulmonary Medicine

Date 2007 Jul 27

PMID 17652506

Citations 34

Authors

Steven M Rowe

Frank Accurso

John P Clancy

Affiliations

Soon will be listed here.

Abstract

Advances in our understanding of cystic fibrosis pathogenesis have led to strategies directed toward treatment of underlying causes of the disease rather than treatments of disease-related symptoms. To expedite evaluation of these emerging therapies, early-phase clinical trials require extension of in vivo cystic fibrosis transmembrane conductance regulator (CFTR)-detecting assays to multicenter trial formats, including nasal potential difference and sweat chloride measurements. Both of these techniques can be used to fulfill diagnostic criteria for the disease, and can discriminate various levels of CFTR function. Full realization of these assays in multicenter clinical trials requires identification of sources of nonbiological intra- and intersite variability, and careful attention to study design and statistical analysis of study-generated data. In this review, we discuss several issues important to the performance of these assays, including efforts to identify and address aspects that can contribute to inconsistent and/or potentially erroneous results. Adjunctive means of detecting CFTR including mRNA expression, immunocytochemical localization, and other methods are also discussed. Recommendations are presented to advance our understanding of these biomarkers and to improve their capacity to predict cystic fibrosis outcomes.

Citing Articles

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?.

Drzymala-Czyz S, Walkowiak J, Colombo C, Alicandro G, Storrosten O, Kolsgaard M iScience. 2024; 27(11):111153.

PMID: 39620135 PMC: 11607544. DOI: 10.1016/j.isci.2024.111153.

Engineered tRNAs suppress nonsense mutations in cells and in vivo.

Albers S, Allen E, Bharti N, Davyt M, Joshi D, Perez-Garcia C Nature. 2023; 618(7966):842-848.

PMID: 37258671 PMC: 10284701. DOI: 10.1038/s41586-023-06133-1.

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.

Silva I, Laselva O, Lopes-Pacheco M J Pers Med. 2022; 12(8).

PMID: 36013270 PMC: 9409685. DOI: 10.3390/jpm12081321.

CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.

Patel S, Bono T, Rowe S, Solomon G Eur Respir Rev. 2020; 29(156).

PMID: 32554756 PMC: 9131734. DOI: 10.1183/16000617.0068-2019.

Optical Nanosensors for Physiological Chloride Detection for Monitoring Cystic Fibrosis Treatment.

Di W, Clark H Anal Methods. 2020; 12(11):1441-1448.

PMID: 32226484 PMC: 7100910. DOI: 10.1039/C9AY02717C.

References

Kerem B, Kerem E . The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet. 1996; 4(2):65-73. DOI: 10.1159/000472174. View

Whitehead F, Couper R, Moore L, Bourne A, Byard R . Dehydration deaths in infants and young children. Am J Forensic Med Pathol. 1996; 17(1):73-8. DOI: 10.1097/00000433-199603000-00014. View

Gill D, Southern K, Mofford K, Seddon T, Huang L, Sorgi F . A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997; 4(3):199-209. DOI: 10.1038/sj.gt.3300391. View

Porteous D, Dorin J, McLACHLAN G, Davidson-Smith H, Davidson H, Stevenson B . Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997; 4(3):210-8. DOI: 10.1038/sj.gt.3300390. View

Walker L, Venglarik C, Aubin G, Weatherly M, McCarty N, Lesnick B . Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am J Respir Crit Care Med. 1997; 155(5):1684-9. DOI: 10.1164/ajrccm.155.5.9154877. View

HARDY J, Davison S, Higgins M, Polycarpou P . Sweat tests in the newborn period. Arch Dis Child. 1973; 48(4):316-8. PMC: 1648362. DOI: 10.1136/adc.48.4.316. View

Beckerman R, Taussig L . Hypoelectrolytemia and metabolic alkalosis in infants with cystic fibrosis. Pediatrics. 1979; 63(4):580-3. View

Knowles M, GATZY J, Boucher R . Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981; 305(25):1489-95. DOI: 10.1056/NEJM198112173052502. View

Shankle W, Azen S, LANDING B . Comparisons of eccrine sweat gland anatomy in genetic, chromosomal, and other diseases, and a suggested procedure for use of sweat gland measurements in differential diagnosis. Teratology. 1982; 25(2):239-45. DOI: 10.1002/tera.1420250213. View

10.

Quinton P . Chloride impermeability in cystic fibrosis. Nature. 1983; 301(5899):421-2. DOI: 10.1038/301421a0. View

11.

Hodson M, Beldon I, Power R, Duncan F, Bamber M, Batten J . Sweat tests to diagnose cystic fibrosis in adults. Br Med J (Clin Res Ed). 1983; 286(6375):1381-3. PMC: 1547859. DOI: 10.1136/bmj.286.6375.1381. View

12.

Quinton P, Bijman J . Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. N Engl J Med. 1983; 308(20):1185-9. DOI: 10.1056/NEJM198305193082002. View

13.

Knowles M, GATZY J, Boucher R . Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest. 1983; 71(5):1410-7. PMC: 437005. DOI: 10.1172/jci110894. View

14.

Knowles M, Stutts M, Spock A, Fischer N, Gatzy J, Boucher R . Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science. 1983; 221(4615):1067-70. DOI: 10.1126/science.6308769. View

15.

Sato K, Sato F . Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest. 1984; 73(6):1763-71. PMC: 437089. DOI: 10.1172/JCI111385. View

16.

Knowles M, Gatzy J, Boucher R . Aldosterone metabolism and transepithelial potential difference in normal and cystic fibrosis subjects. Pediatr Res. 1985; 19(7):676-9. DOI: 10.1203/00006450-198507000-00008. View

17.

Frizzell R, Halm D, Rechkemmer G, Shoemaker R . Chloride channel regulation in secretory epithelia. Fed Proc. 1986; 45(12):2727-31. View

18.

Dodge J, Custance J, Goodchild M, Laing S, Vaughan M . Paradoxical effects of essential fatty acid supplementation on lipid profiles and sweat electrolytes in cystic fibrosis. Br J Nutr. 1990; 63(2):259-71. DOI: 10.1079/bjn19900113. View

19.

Anbar R, Lapey A, Khaw K, Spragg J, Strieder D, Shaw L . Does lithium carbonate affect the ion transport abnormality in cystic fibrosis?. Pediatr Pulmonol. 1990; 8(2):82-8. DOI: 10.1002/ppul.1950080205. View

20.

Kerem E, Corey M, Kerem B, Rommens J, Markiewicz D, Levison H . The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med. 1990; 323(22):1517-22. DOI: 10.1056/NEJM199011293232203. View